The UPMC Hillman Cancer Center, previously titled the University of Pittsburgh Cancer Institute, is a National Cancer Institute-designated Comprehensive Cancer Center located in the Hillman Cancer Center in the Shadyside neighborhood of Pittsburgh, Pennsylvania, United States, adjacent to UPMC Shadyside.

During the past decade, University of Pittsburgh Cancer Institute (UPCI) conducted 210 clinical trials. In the 10-year time frame, 210 clinical trials started and 134 clinical trials were completed, i.e. on average, 63.8% percent of trials that started reached the finish line to date. In the past 5 years, 61 clinical trials started and 58 clinical trials were completed. i.e. 95.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University of Pittsburgh Cancer Institute (UPCI)" #1 sponsor was "National Cancer Institute (NCI)" with 228 trials, followed by "Radiation Therapy Oncology Group" with 36 trials sponsored, "Alliance for Clinical Trials in Oncology" with 29 trials sponsored, "SWOG Cancer Research Network" with 29 trials sponsored and "Eastern Cooperative Oncology Group" with 29 trials sponsored. Other sponsors include 160 different institutions and companies that sponsored additional 86 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University of Pittsburgh Cancer Institute (UPCI)" #1 collaborator was "National Cancer Institute (NCI)" with 190 trials as a collaborator, "NRG Oncology" with 24 trials as a collaborator, "Canadian Cancer Trials Group" with 12 trials as a collaborator, "Eastern Cooperative Oncology Group" with 11 trials as a collaborator and "Cancer and Leukemia Group B" with 10 trials as a collaborator. Other collaborators include 125 different institutions and companies that were collaborators in the rest 83 trials.

According to Clinical.Site data, the most researched conditions in "University of Pittsburgh Cancer Institute (UPCI)" are "Lung Cancer" (16 trials), "Recurrent Ovarian Carcinoma" (15 trials), "Brain and Central Nervous System Tumors" (14 trials), "Head and Neck Cancer" (14 trials) and "Stage IV Lung Cancer AJCC v8" (14 trials). Many other conditions were trialed in "University of Pittsburgh Cancer Institute (UPCI)" in a lesser frequency.

Most popular intervention types in "University of Pittsburgh Cancer Institute (UPCI)" are "Drug" (413 trials), "Other" (191 trials), "Biological" (176 trials), "Procedure" (135 trials) and "Radiation" (91 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (120 trials), "Computed Tomography" (58 trials), "Quality-of-Life Assessment" (58 trials), "Biospecimen Collection" (55 trials) and "Carboplatin" (49 trials). Other intervention names were less common.

The vast majority of trials in "University of Pittsburgh Cancer Institute (UPCI)" are 421 trials for "All" genders, 62 trials for "Female" genders and 25 trials for "Male" genders.

Currently, there are NaN active trials in "University of Pittsburgh Cancer Institute (UPCI)". 2 are not yet recruiting, 85 are recruiting, 151 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 213 completed trials in University of Pittsburgh Cancer Institute (UPCI), 11 suspended trials, and 39 terminated clinical trials to date.

Out of the total trials that were conducted in University of Pittsburgh Cancer Institute (UPCI), 117 "Phase 1" clinical trials were conducted, 278 "Phase 2" clinical trials and 149 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 10 trials that are defined as “Not Applicable".